BioSignia Offers Individualized Report on Your Health to Combat Heart Disease, the No. 1 Killer in the U.S.

Heart disease is the leading cause of death in the United States, but now a powerful one-page report developed by BioSignia can help monitor your risks of developing specific chronic preventable cardiovascular diseases, such as heart disease and stroke.

BioSignia Announces Agreement to Deliver Chronic Disease Prediction Technology Through Regional Pharmacy Chain Kerr Drug

BioSignia, a leading preventative healthcare technology company, today announced the signing of a licensing agreement with regional pharmacy chain Kerr Drug. BioSignia’s health risk assessment (HRA) engine significantly improves prevention and management of chronic diseases by focusing on individualized disease risk assessment (DRA).

BioSignia Rolls Out National Marketing Campaign With 919 Marketing Company

BioSignia, a leading technology company focused on innovative solutions for chronic disease prevention and management, today announced the signing of a marketing services agreement with 919 Marketing Company. With offices in Holly Springs N.C. and Washington D.C., 919 is a nationally recognized marketing consulting and public relations firm focused on the health and wellness market.